Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RBP-6000

Small molecule · developed by Indivior

Phase 3 Most advanced trial (none active)
1 Registered trials

What is RBP-6000?

RBP-6000 is an extended-release formulation of buprenorphine given as monthly subcutaneous injections, with doses adjusted between 100 mg and 300 mg. It is studied in patients with opioid use disorder and opioid-related disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
atrigel buprenorphine
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Indivior Inc.
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02896296 Phase 3 Opioid Use Disorder Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Opioid Use DisorderOpioid-related Disorders

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.